Alnylam Pharmaceuticals, Inc. (ALNY)
R&D to Revenue
35.66%
Fiscal year · Period ending:

ALNY R&D to Revenue
What is r&d to revenue?
R&D spending as percentage of revenue.
ALNY r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.
| Period ending | R&D to Revenue | Change |
|---|---|---|
| 35.6624% | −14.43 pts | |
| 50.0939% | −4.84 pts | |
| 54.9373% | −30.18 pts | |
| 85.1166% | −8.71 pts | |
| 93.8254% | −39.04 pts | |
| 132.8629% | −165.25 pts | |
| 298.1179% | −376.60 pts | |
| 674.721% | +240.26 pts | |
| 434.4637% | −376.39 pts | |
| 810.8569% | +138.07 pts | |
| 672.7863% | +296.51 pts | |
| 376.2762% | +136.79 pts | |
| 239.4831% | +109.74 pts | |
| 129.74% | +9.76 pts | |
| 119.9838% | +13.64 pts | |
| 106.3404% | −1.81 pts | |
| 108.1535% | +7.40 pts | |
| 100.7487% | −136.37 pts | |
| 237.1181% | +52.20 pts | |
| 184.9165% | −432.98 pts | |
| 617.8971% | +42.79 pts | |
| 575.1052% | −6,866.37 pts | |
| 7,441.4773% | +7,441.48 pts | |
| 0% | — |
Frequently asked questions: ALNY r&d to revenue
What is Alnylam Pharmaceuticals, Inc. (ALNY)'s current r&d to revenue?
Alnylam Pharmaceuticals, Inc. (ALNY)'s latest reported r&d to revenue (Fiscal year) is 35.66% as of Dec 31, 2025. R&D spending as percentage of revenue.
How much historical r&d to revenue data is available for ALNY?
Stock Alarm Pro provides 24 dated annual fiscal periods observations for Alnylam Pharmaceuticals, Inc. (ALNY)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.
How can I compare ALNY's r&d to revenue to peers or set an alert?
You can open ALNY's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on ALNY delivered by push, email, or phone call.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance